Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Jun 11, 2025
- Accession no.
- 0001437749-25-020045
- Filed
- Jun 11, 2025
- Trade date
- Jun 8-9, 2025
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $38.0K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2025 | Ordinary Shares | MOption exerciseAcquired | +10,000 | – | – | 158,540 | Direct | |
| Jun 9, 2025 | Ordinary Shares | SSaleDisposed | −5,162 | $7.37 | −$38,043.94 | 153,378 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2025 | Ordinary Shares | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 10,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.